Diabetes

Pharmacists can help patients select products and provide education on how to use them.

Investigators have found that although the composition and function the gut microbiome changes throughout the day in most people, these variations stop in patients with type 2 diabetes (T2D).

Although hypoglycemia can be fatal, continuous glucose monitoring may reduce risk.

The rate of weight gain during pregnancy, use of insulin pumps, and CGMS have increased in women with type 1 diabetes, according to new research.

Researchers looked at the effects of a genetic risk score for developing T2D as an adult on metabolism, measured from blood samples taken from participants in the study when they were aged 8, 16, 18, and 25 years.

Being able to predict life expectancy will help care providers decide which A1c target ranges are the best for each patient with diabetes.

Visual impairment confers a tremendous psychosocial burden, yet up to half of atrisk patients skip annual eye examinations. symposium held in conjunction with the Asembia Specialty Pharmacy Summit, noting that up to 17% of cases of blindness can be attributed to diabetic eye disease.

Pharmacy Times spoke with Robert Schumm, MBA, president of Ascensia Diabetes Care, about the challenges that patients with diabetes are facing during the COVID-19 pandemic.

A phase 2 clinical trial demonstrated that a 2-week course of teplizumab was able to delay the onset of clinical type 1 diabetes by 3 years compared with patients taking a placebo.

Using artificial intelligence (AI) and automated monitoring, researchers and physicians at Oregon Health & Science University (OHSU) have designed a method to help people with type 1 diabetes better manage their glucose levels.

Ertugliflozin is a relatively new addition to the SGLT2 inhibitor class of medication.

According to a recent study presented at the ADA’s 80th Scientific Sessions, youth and young adults with type 1 diabetes (T1D) in the United States today have worse glycemic control than prior generations.

Treatment of recently diagnosed patients with type 1 diabetes (T1D) with anti-IL-21 and liraglutide for 54 weeks was found to be safe and resulted in sustained insulin secretion and lower insulin dose.

The DPPOS is the long-term follow-up of the Diabetes Prevention Program (DPP), a multicenter trial conducted from 1996 to 2001 that established the success of either an intensive lifestyle program or treatment with metformin to prevent or delay the development of T2D in individuals who were considered at high risk for developing the disease.

Oral insulin (OI) slows insulin decline in those at high risk for type 1 diabetes (T1D), according to a poster session at the American Diabetes Association’s 80th virtual Scientific Sessions.

There have not been many evaluations of the prevalence of, and factors associated with, use of DSME/S and support programs in newly diagnosed patients with type 2 diabetes (T2D) in Louisiana, according to the study authors.

The slowed metabolic decline among the OI trial participants at highest risk was assessed and defined by the DPT1 Risk Scores over a 6.75 threshold.

The TEDDY study also aims to identify environmental triggers that cause the immune destruction of beta cells.

The results of the study demonstrated that dapagliflozin was able to reduce new-onset diabetes by 32%.

FreeStyle Libre continuous glucose monitoring (CGM) technology was linked with significant reduction in hemoglobin A1c levels for people living with type 2 diabetes on either long-acting insulin or non-insulin therapy.

The results of the real-world, observational study were presented by Eli Lilly during the American Diabetes Association's 80th Virtual Scientific Sessions.

Humana and PQS are piloting the first diabetes outcomes-based program within the EQuIPP platform that incentivizes improvement across unique diabetes control measures.

Dapagliflozin is typically used as a second line GLM in T2D and often added to metformin.

A study of more than 9000 people finds overall need for better access to psychological and other non-medical diabetes care for people living with diabetes and their caregivers.

Managing diabetes in rural areas is difficult due to limited access to specialty care and self-management programs.